Spectrawave

Company profile

About Spectrawave

SpectraWAVE Inc. is an innovator in Enhanced Vascular Imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging. The company provides advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease affecting more than 300 million people worldwide. SpectraWAVE's flagship HyperVue Imaging System is an intravascular imaging platform that combines DeepOCT (next generation comprehensive optical coherence tomography) and NIRS (near-infrared spectroscopy) into the Enhanced Vascular Imaging (EVI) segment to provide detailed structural and compositional images of the coronary arteries during percutaneous coronary interventions. The system features rapid setup, acquisition, and automated AI image analysis to support clinical decision-making. The company's X1-FFR is an angiography-derived, AI-enabled physiology solution that calculates Fractional Flow Reserve (FFR) from a single coronary angiogram, providing a non-invasive ischemia assessment and turning routine X-ray images into coronary physiology data for simplified percutaneous coronary intervention workflows. Both technologies have received FDA clearance as Class 2 medical devices. In December 2025, Royal Philips announced an agreement to acquire SpectraWAVE to expand its image-guided therapy portfolio and integrate SpectraWAVE's technologies with Philips' industry-leading Azurion platform, supporting better outcomes for cardiac patients through the convergence of intravascular imaging, coronary physiology, and AI.

Company description · Spectrawave official website